35 related articles for article (PubMed ID: 38387931)
1. Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Li C; Deng C; Wu P; Liu K; Huang X; Li M; Chen X; Geng S; Lai P; Weng J; Du X
Clin Transl Sci; 2024 Jan; 17(1):e13711. PubMed ID: 38129985
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G; Jabbour E; Borthakur G; Kadia T; Ravandi F; Chien K; Pemmaraju N; Hammond D; Dong XQ; Huang X; Schneider H; John R; Kanagal-Shamana R; Loghavi S; Kantarjian H; Garcia-Manero G
Br J Haematol; 2024 Mar; 204(3):898-909. PubMed ID: 37946611
[TBL] [Abstract][Full Text] [Related]
3. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G; Thongon N; Rodriguez-Sevilla JJ; Ma F; Ganan-Gomez I; Yang H; Kim YJ; Adema V; Wildeman B; Tanaka T; Darbaniyan F; Al-Atrash G; Dwyer K; Loghavi S; Kanagal-Shamanna R; Song X; Zhang J; Takahashi K; Kantarjian H; Garcia-Manero G; Colla S
Cell Rep Med; 2024 May; ():101585. PubMed ID: 38781960
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report.
Diral E; Catalano G; Cicinelli MV; Distefano A; Mastaglio S; Vago L; Lupo Stanghellini MT; Bernardi M; Ponzoni M; Ciceri F; Carrabba MG
Front Oncol; 2024; 14():1399894. PubMed ID: 38756666
[TBL] [Abstract][Full Text] [Related]
5. The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b-cell lymphoma.
Romano A; Giusti M; Di Giorgio M; Lumera G; Laura Parrinello N; Cosentino S; Ippolito M; Villari L; Alberto Palumbo G; Di Raimondo F; Santo Signorelli S
Clin Case Rep; 2021 Sep; 9(9):e03817. PubMed ID: 34589219
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
[TBL] [Abstract][Full Text] [Related]
7. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
9. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
10. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
11. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].
Li X; Wang Y; Guo YJ; Niu ZY; Ma L; Zhou XQ; Zhang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):257-261. PubMed ID: 38387931
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]